The role of URO17™ biomarker to enhance diagnosis of urothelial cancer in new haematuria patients – First European Data

Keyphrases

• Urothelial Cancer 100%
• European Data 100%
• Hematuria 100%
• Tumor 66%
• Urine Samples 66%
• Malignancy 66%
• Cystoscopic 66%
• Immunomarkers 66%
• Bladder Cancer 66%
• Novel Biomarkers 33%
• Pathologist 33%
• Diagnostic Medicine 33%
• Urine Detection 33%
• Anonymized 33%
• Malignant Cells 33%
• Diagnostic Accuracy 33%
• Invasive Procedures 33%
• Radiological Tests 33%
• Diagnostic Ability 33%
• Biomarker Research 33%
• Histological Investigation 33%
• Urinary Bladder Cancer 33%
• Urine Test 33%
• Non-muscle Invasive Bladder Cancer (NMIBC) 33%
• Current Smokers 33%
• Urology Department 33%
• Non-smokers 33%
• Validation Studies 33%
• New Patients 33%
• Risk of Harm 33%
• Detection Test 33%
• Keratin 17 33%
• Diagnostic Sensitivity 33%
• Positive Predictive Value 33%
• Overall Sensitivity 33%
• Carcinoma in Situ 33%
• Cystoscopy 33%
• Ex-smokers 33%
• Negative Predictive Value 33%
• Replication Cycle 33%
• Histology 33%
• Urothelial Malignancy 33%
• Oncoprotein 33%
• Urinary Biomarkers 33%
• Primary Care 33%
• Ethics Protocol 33%
• Highly Sensitive 33%

Medicine and Dentistry

• Microhematuria 100%
• Bladder Cancer 100%
• Biological Marker 100%
• Urothelial Cancer 100%
• Cancer 75%
• Urine Sampling 50%
• Neoplasm 50%
• Diagnosis 50%
• Medicine 25%
• Smoking 25%
• Patient Referral 25%
• Hematuria 25%
• Keratin 17 25%
• Oncoprotein 25%
• Pathologist 25%
• Primary Health Care 25%
• Invasive Procedure 25%
• Urinalysis 25%
• Cystoscopy 25%
• Urology 25%
• Cytotechnology 25%
• Diagnostic Accuracy 25%
• Carcinoma in Situ 25%
• Urinary System 25%
• Biopsy Technique 25%